Similar articles

• Adalimumab vs. etanercept in psoriasis.

  Downs AM. Downs AM. Clin Exp Dermatol. 2007 Sep;32(5):593. doi: 10.1111/j.1365-2230.2007.02494.x. Clin Exp Dermatol. 2007. PMID: 17692064 No abstract available.
• Switching biologics for psoriasis.

  Ormerod AD. Ormerod AD. Br J Dermatol. 2010 Oct;163(4):667-9. doi: 10.1111/j.1365-2133.2010.09999.x. Br J Dermatol. 2010. PMID: 20854399 No abstract available.
• Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.

  Woolf RT, Smith CH, Robertson K, Barker JN. Woolf RT, et al. Br J Dermatol. 2010 Oct;163(4):889-92. doi: 10.1111/j.1365-2133.2010.09893.x. Epub 2010 Jul 28. Br J Dermatol. 2010. PMID: 20854408 Review. No abstract available.
• [Intermittent treatment regimens and the rational (efficient) use of biologic agents in psoriasis].

  Moreno-Ramírez D. Moreno-Ramírez D. Actas Dermosifiliogr. 2011 May;102(4):241-3. doi: 10.1016/j.ad.2011.02.003. Epub 2011 Apr 9. Actas Dermosifiliogr. 2011. PMID: 21481332 Spanish. No abstract available.
• [What is the impact of the new clinical trial data? What are the lessons for patient management?].

  Passeron T, Boulinguez S. Passeron T, et al. Ann Dermatol Venereol. 2010 May;137(5 Suppl 1):11-5. doi: 10.1016/S0151-9638(10)70017-X. Ann Dermatol Venereol. 2010. PMID: 20510174 Review. French. No abstract available.